3 New Drug Launches of 2020 -- and the Stocks That Could Win Big
Social distancing measures aimed at controlling the coronavirus pandemic have slowed down a lot of government agencies, but they haven't prevented regulators from reviewing new drug applications at a rapid pace. The FDA has already approved 35 novel new drugs this year, and keeping up with all of them is a task few of us have time for.
Recently, Evaluate, a healthcare analytics service, ranked recently approved drugs according to consensus sales forecasts from industry analysts. Here's what investors should know about new products that rose to the top from Immunomedics (NASDAQ: IMMU), Esperion (NASDAQ: ESPR), and Bristol Myers Squibb (NYSE: BMY).
Image source: Getty Images.
Source Fool.com
